Teicoplanin is a semisynthetic glycopeptide antibiotic that significantly inhibits SARS-CoV-2. It acts on an early stage of the viral life cycle by inhibiting the low-pH required for cleavage of the viral spike protein. Evidence about Teicoplanin showed that there is a problem about the effective dose required to inhibit the virus and more studies are required. (Zhang et al., 2020c).